Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Biological therapy of squamous cell cancers of the head and neck

  • Chapter
Principles of Cancer Biotherapy

  • 1009 Accesses

This category includes squamous cell cancers that originate in the mouth, oropharynx, nasopharynx, and larynx. Many of the cancers are associated with smoking and other forms of tobacco abuse that are local irritants and mutants, and some are caused by human papilloma virus, and other viruses. Primary therapy typically includes surgery and/or radiation therapy, and increasingly chemotherapy as part of organ sparing approaches that minimize the morbidity associated with extensive surgery in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568–77.

    Article  CAS  PubMed  Google Scholar 

  2. Benasso M, Merlano M, Blengio F, et al. Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 1993;16:465–8.

    Article  CAS  PubMed  Google Scholar 

  3. Bensmaine ME, Azli N, Domenge C, et al. Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fl uorouracil in recurrent and/or metastatic carcinoma of head and neck. Am J Clin Oncol 1996;19:249–54.

    Article  CAS  PubMed  Google Scholar 

  4. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78.

    Article  CAS  PubMed  Google Scholar 

  5. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fl uorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2866–72.

    Article  CAS  PubMed  Google Scholar 

  6. Buechler M, Mukherji B, Chasin W, Nathanson L. High dose meth-otrexate with and without BCG therapy in advanced head and neck malignancy. Cancer 1979;43:1095–100.

    Article  CAS  PubMed  Google Scholar 

  7. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646–54.

    Article  PubMed  Google Scholar 

  8. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568–76.

    Article  CAS  PubMed  Google Scholar 

  9. Chang AE, Li Q, Jiang G, et al. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck 2003;25:198–209.

    Article  PubMed  Google Scholar 

  10. Cheng VS, Suit HD, Wang CC, et al. Clinical trial of Corynebacterium parvum (intra-lymph-node and intravenous) and radiation therapy in the treatment of head and neck carcinoma. Cancer 1982;49:239–44.

    Article  CAS  PubMed  Google Scholar 

  11. Cortesina G, De Stefani A, Galeazzi E et al. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 1991;13:125–31.

    Article  CAS  PubMed  Google Scholar 

  12. Cortesina G, De Stefani A, Galeazzi E, et al. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant inter-leukin 2 injected perilymphatically. Br J Cancer 1994;69:572–6.

    Article  CAS  PubMed  Google Scholar 

  13. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646–54.

    Article  PubMed  Google Scholar 

  14. De Stefani A, Forni G, Rogona R, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 2002;95:90–7.

    Article  PubMed  Google Scholar 

  15. Feinmesser R, Hardy B, Sadov R, et al. Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine. Arch Otolaryngol Head Neck Surg 2003;129:874–81.

    Article  PubMed  Google Scholar 

  16. Gravis G, Pech-Gourgh F, Viens P, et al. Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma. Anticancer Drugs 1999;10:369–74.

    Article  CAS  PubMed  Google Scholar 

  17. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005a;23:5578–87.

    Article  CAS  Google Scholar 

  18. Herold-Mende C, Karcher J, Dyckhoff G, Schirrmacher V. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modifi ed autologous tumor cell vaccine. Adv Otorhinolaryngol 2005;62:173–83.

    PubMed  Google Scholar 

  19. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795–801.

    Article  CAS  PubMed  Google Scholar 

  20. Hussain M, Benedetti J, Smith RE, et al. Evaluation of 96-hour infusion fl uorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. Cancer 1995;76:1233–7.

    Article  CAS  PubMed  Google Scholar 

  21. Kerrebijn JD, Simons PJ, Balm AJ, et al. Thymostimulin enhancement of T-cell infi ltration into head and neck squamous cell carcinoma. Head Neck 1996;18:335–42.

    Article  CAS  PubMed  Google Scholar 

  22. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441–50.

    Article  CAS  PubMed  Google Scholar 

  23. Kimura T, Suzuki K, Motai H, et al. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Acta Otolaryngol Suppl 1996;525:135–41.

    CAS  PubMed  Google Scholar 

  24. Lam P, Yuen AP, Ho CM, et al. Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. Eur J Surg Oncol 2001;27:750–3.

    Article  CAS  PubMed  Google Scholar 

  25. Lippman SM, Kessler JF, Al-Sarraf M, et al. Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial. Invest New Drugs 1988;6:51–6.

    Article  CAS  PubMed  Google Scholar 

  26. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15–20.

    Article  CAS  PubMed  Google Scholar 

  27. Mantovani G, Bianchi A, Curreli L, et al. Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study. Biotherapy 1994;8:91–8.

    CAS  Google Scholar 

  28. Mantovani G, Gebbia V, Airoldi M, et al. Neo-adjuvant chemo-immuno therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fl uorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. Cancer Immunol Immunother 1998;47:149–56.

    Article  CAS  PubMed  Google Scholar 

  29. Mattijssen V, De Mulder PH, De Graeff A, et al. Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann Oncol 1994;5:957–60.

    CAS  PubMed  Google Scholar 

  30. Mussche RA, Kluyskens P. Prognosis of primarily treated localized laryngeal carcinoma ameliorated through levamisole treatment: a randomized pilot study. Oncology 1980;37:329–35.

    Article  CAS  PubMed  Google Scholar 

  31. Neifeld JP, Terz JJ, Kaplan AM, Lawrence W Jr. Adjuvant Corynebacterium parvum immunotherapy for squamous cell epi-theliomas of the oral cavity, pharynx, and larynx. J Surg Oncol 1985;28:137–45.

    Article  CAS  PubMed  Google Scholar 

  32. Nikolaou AC, Fountzilas G, Daniilidis I. Treatment of unresect-able recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study. J Laryngol Otol 1996;110:857–61.

    CAS  Google Scholar 

  33. Olivari AJ, Glait HM, Guardo A, et al. Levamisole in squamous cell carcinoma of the head and neck. Cancer Treat Rep 1979;63:983–90.

    CAS  PubMed  Google Scholar 

  34. Padmanabhan TK, Balaram P, Vasudevan DM. Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. I. A three-year clinical follow up. Neoplasma 1987;34:627–32.

    CAS  Google Scholar 

  35. Papac R, Minor DR, Rudnick S, et al. Controlled trial of metho-trexate and Bacillus Calmette-Guérin therapy for advanced head and neck cancer. Cancer Res 1978;38:3150–3.

    CAS  PubMed  Google Scholar 

  36. Perry CF, Stevens M, Rabie I, et al. Chemoprevention of head and neck cancer with retinoids: a negative result. Arch Otolaryngol Head Neck Surg 2005;131:198–203.

    Article  PubMed  Google Scholar 

  37. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cispla-tin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072–8.

    Article  CAS  PubMed  Google Scholar 

  38. Recchia F, Lalli A, Lombardo M, et al. Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study. Cancer 2001;92:814–21.

    Article  CAS  PubMed  Google Scholar 

  39. Recchia F, Candeloro G, Di Staso M, et al. Maintenance immuno-therapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J Immunother 2008;31:413–9.

    Article  CAS  PubMed  Google Scholar 

  40. Riechelmann H, Wiesneth M, Schauwecker P, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007;56:1397–406.

    Article  CAS  PubMed  Google Scholar 

  41. Richman SP, Livingston RB, Gutterman JU, et al. Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study. Cancer Treat Rep 1976;60:535–9.

    CAS  PubMed  Google Scholar 

  42. Richtsmeier WJ, Koch WM, McGuire WP, et al. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg 1990;116:1271–7.

    CAS  PubMed  Google Scholar 

  43. Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005;23:9089–96.

    Article  CAS  PubMed  Google Scholar 

  44. Roth AD, Abele R, Alberto P. 13-cis-retinoic acid plus interferonalpha: a phase II clinical study in squamous cell carcinoma of the lung and the head and neck. Oncology 1994;51:84–6.

    Article  CAS  PubMed  Google Scholar 

  45. Schantz SP, Dimery I, Lippman SM, et al. A phase II study of inter-leukin-2 and interferon-alpha in head and neck cancer. Invest New Drugs 1992;10:217–23.

    Article  CAS  PubMed  Google Scholar 

  46. Schulof RS. Thymic peptide hormones: basic properties and clinical applications in cancer. Crit Rev Oncol Hematol 1985;3:309–76.

    Article  CAS  PubMed  Google Scholar 

  47. Seixas-Silva JA Jr, Richards T, Khuri FR, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg 2005;131:304–7.

    Article  PubMed  Google Scholar 

  48. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001;19:3010–7

    CAS  PubMed  Google Scholar 

  49. Suen JY, Richman SP, Livingston RB, et al. Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck. Am J Surg 1977;134:474–8.

    Article  CAS  PubMed  Google Scholar 

  50. Taylor SG 4th, Sisson GA, Bytell DE, Raynor WJ Jr. A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Arch Otolaryngol 1983;109:544–9.

    PubMed  Google Scholar 

  51. Timar J, Forster-Horvath C, Lukitis J, et al. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer — a multicenter phase I/II clinical Trial. Laryngoscope 2003;113:2206–17.

    Article  CAS  PubMed  Google Scholar 

  52. Toma S, Bonelli L, Sartoris A, et al. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 2004;11:1297–305.

    CAS  PubMed  Google Scholar 

  53. Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer 1993;71:2326–31.

    Article  CAS  PubMed  Google Scholar 

  54. Valavaara R, Kortekangas AE, Nordman E, et al. Interferon combined with irradiation in the treatment of operable head and neck carcinoma. A pilot study. Acta Oncol 1992;31:429–31.

    CAS  Google Scholar 

  55. van Herpen CM, van der Laak JA, de Vries IJ, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifi es locoregional lymph node architecture and induces natural killer cell infi ltration in the primary tumor. Clin Cancer Res 2005;11:1899–909.

    Article  PubMed  Google Scholar 

  56. van Sándwich N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000;92:977–86.

    Google Scholar 

  57. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the effi cacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171–7.

    Article  CAS  PubMed  Google Scholar 

  58. Vlock DR, Snyderman CH, Johnson JT, et al. Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol 1994;15:134–9.

    CAS  PubMed  Google Scholar 

  59. Vlock DR, Andersen J, Kalish LA, et al. Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol 1996;19:433–42.

    CAS  PubMed  Google Scholar 

  60. Voravud N, Lippman SM, Weber RS, et al. Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer. Invest New Drugs 1993;11:57–60.

    Article  CAS  PubMed  Google Scholar 

  61. Wanebo HJ, Hilal EY, Pinsky CM, et al. Randomized trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Cancer Treat Rep 1978;62:1663–9.

    CAS  PubMed  Google Scholar 

  62. Woods JE, DeSanto LW, Ritts RE Jr. A controlled study of combined methotrexate, BCG, and INH therapy for squamous cell carcinoma of the head and neck. Surg Clin North Am 1977;57:76–78.

    Google Scholar 

  63. Vogl SE, Schoenfeld DA, Kaplan BH, et al. Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 1982;50:2295–300

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hoag Cancer Center, Newport Beach, CA, USA

    Robert O. Dillman

  2. University of California, Irvine, CA, USA

    Robert O. Dillman

Authors
  1. Robert O. Dillman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hematology-Oncology Associates of Southeast Missouri Hospital, Southeast Medical Plaza, Cape Girardeau, MO, USA

    Robert K. Oldham

  2. Hoag Cancer Center, Newport Beach, CA, USA

    Robert O. Dillman

  3. University of California, Irvine, CA, USA

    Robert O. Dillman

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Dillman, R.O. (2009). Biological therapy of squamous cell cancers of the head and neck. In: Oldham, R.K., Dillman, R.O. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2289-9_29

Download citation

Publish with us

Policies and ethics

Search

Navigation